Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis

• Published in: American journal of respiratory and critical care medicine Vol. 200; no. 3; pp. 336 - 347
• Main Authors: Newton, Chad A., Zhang, David, Oldham, Justin M., Kozlitina, Julia, Ma, Shwu-Fan, Martinez, Fernando J., Raghu, Ganesh, Noth, Imre, Garcia, Christine Kim
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.08.2019
• Subjects: Aged; Anti-Inflammatory Agents - therapeutic use; Anticoagulants; Azathioprine - therapeutic use; Cell division; Clinical trials; Cohort Studies; Deoxyribonucleic acid; DNA; Female; Humans; Idiopathic Pulmonary Fibrosis - mortality; Idiopathic Pulmonary Fibrosis - pathology; Idiopathic Pulmonary Fibrosis - therapy; Immunosuppressive agents; Immunosuppressive Agents - therapeutic use; Leukocytes - pathology; Lung Transplantation; Male; Medicine; Middle Aged; Mortality; Original; Prednisone - therapeutic use; Pulmonary fibrosis; Senescence; Survival Rate; Telomerase; Telomere - pathology; Transplants & implants; New York; California; clinical trial; diffuse parenchymal lung disease; pharmacogenomic; IPF; telomeres

Immunosuppression was associated with adverse events for patients with idiopathic pulmonary fibrosis (IPF) in the PANTHER-IPF (Evaluating the Effectiveness of Prednisone, Azathioprine and -Acetylcysteine in Patients with IPF) clinical trial. The reason why some patients with IPF experience harm is u...